

# Effectiveness of therapeutic hypothermia for mild neonatal encephalopathy

# A protocol for systematic review and meta-analysis

Tingting Zheng, MB<sup>a</sup>, Xini Liu, MB<sup>b</sup>, Xuechun Chen, MB<sup>c,\*</sup>💿

# Abstract

**Background:** Neonates with moderate to severe encephalopathy benefit significantly from therapeutic hypothermia, with reduced risk of death or disability. However, the need for therapeutic hypothermia for mild neonatal encephalopathy (NE) remains unclear. Therefore, we conducted a protocol for systematic review and meta-analysis to provide evidence supporting therapeutic hypothermia for term or near term neonates with mild NE, including findings of recent long-term outcome studies, as well as novel adjunctive therapies to augment neurodevelopmental outcomes for neonates with NE who receive therapeutic hypothermia.

**Methods:** Two independent researchers performed a systematic literature search in different electronic databases including PubMed, the Cochrane Center Controlled Trials Register, EMBASE, Medline, Ovid, Chinese National Knowledge Infrastructure, Chinese Biomedical Literature Database, and Wanfang Database without any restrictions of languages and date. Two reviewers will screen the records and include quality studies according to inclusion criteria independently. Two reviewers will assess the risk of bias of the included studies by the "Risk of Bias Assessment Tool" of the Cochrane Handbook for randomized controlled trials. Statistical analysis will be performed with Review Manager software 5.3.

Results: A synthesis of current evidence of therapeutic hypothermia for treating mild NE will be provided in this protocol.

Conclusion: The results of this study will provide a theoretical basis for the clinical use of therapeutic hypothermia in mild NE.

Abbreviations: NE = neonatal encephalopathy, RCT = randomized controlled trial.

Keywords: meta-analysis, neonatal encephalopathy, systematic review, therapeutic hypothermia

# 1. Introduction

Neonatal encephalopathy (NE) is identified by the World Health Organization as one of the 10 leading causes of lost years of life and is extremely expensive in lifetime costs and in emotional distress for individuals and families.<sup>[1]</sup> Although NE is traditionally attributed to birth asphyxia, population-based studies have consistently observed that most NE and some of the subset of NE considered to be hypoxic-ischemic in origin occurs in infants who have not experienced acute peripartum or intrapartum events.<sup>[2]</sup> NE was characterized by a subnormal level of consciousness, depressed tone, and reflexes, with or without seizures and often with impaired respiration and feeding abilities (both of presumed central origin).<sup>[3–5]</sup> It is defined as mild, moderate, or severe based on the Sarnat scoring system.<sup>[6]</sup>

Neonates with mild NE have not been included in previous trials of therapeutic interventions because they were previously thought to have neurodevelopmental outcomes similar to those without evidence of NE.<sup>[7]</sup> In the therapeutic hypothermia era, reviews have found that 20% to 40% of neonates with mild NE (varying definitions) have abnormal short and long-term outcomes.<sup>[8,9]</sup> In clinical practice, providers are becoming increasingly concerned about neuroprotection for neonates with mild NE, as there is a trend towards providing therapeutic

Funding: Hainan Provincial Health Commission (20A200449).

Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

Received: 9 March 2022 / Received in final form: 10 March 2022 / Accepted: 15 March 2022 http://dx.doi.org/10.1097/MD.000000000029175

TZ and XL have contributed equally to this work.

The authors have no conflicts of interest to disclose.

Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.

<sup>&</sup>lt;sup>a</sup> Department of Pediatrics, the First Affiliated Hospital of Hainan Medical College, Hainan, China, <sup>b</sup> Department of Pediatric Emergency, the First Affiliated Hospital of Hainan Medical College, Hainan, China, <sup>c</sup> Department of Respiratory Medicine, Union Jiangbei Hospital of Huazhong University of Science and Technology, Hubei, China.

<sup>\*</sup> Correspondence: Xuechun Chen, Union Jiangbei Hospital of Huazhong University of Science and Technology, Hubei, China (e-mail: kiysg53@163.com).

This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Zheng T, Liu X, Chen X. Effectiveness of therapeutic hypothermia for mild neonatal encephalopathy: a protocol for systematic review and meta-analysis. Medicine 2022;101:20(e29175).

hypothermia to these babies without clinical evidence of benefit.<sup>[10]</sup> Neonates with mild NE initially appear well with few overt signs of neurological injury. However, the effects of therapeutic hypothermia for mild NE have never been systematically evaluated. Therefore, we conducted a protocol for systematic review and meta-analysis to provide evidence supporting therapeutic hypothermia for term or near term neonates with NE, including findings of recent long-term outcome studies, as well as novel adjunctive therapies to augment neurodevelopmental outcomes for neonates with NE who receive therapeutic hypothermia.

## 2. Methods

#### 2.1. Study registration

This systematic review has been registered on Open Science Framework (Registration number: 10.17605/OSF.IO/GA5HK) and will be performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocol statement guidelines.<sup>[11]</sup> Ethical approval was not required for this study as all the research materials are derived from published studies.

#### 2.2. Selection criteria

Randomized controlled trials (RCTs) comparing selective head or whole-body cooling with usual care in term or near-term infants ( $\geq$ 36 weeks) with mild NE after perinatal asphyxia were eligible. Perinatal asphyxia required at least one of the following criteria: evidence of intra-partum catastrophe, fetal or neonatal metabolic acidosis, and/or resuscitation at birth. Mild NE was not defined separately but was based on a clinical neurological examination performed within 6 hours of birth, as reported in the individual studies. Main outcomes were the composite of death or moderate or severe disability at or beyond 18 months of age. The exclusion criteria were as follows: reviews, letters, conferences abstract, case reports or series, comments, and animal experiment.

#### 2.3. Literature search

Two independent researchers performed a systematic literature search in different electronic databases including PubMed, the Cochrane Center Controlled Trials Register, EMBASE, Medline, Ovid, Chinese National Knowledge Infrastructure, Chinese Biomedical Literature Database, and Wanfang Database without any restrictions of languages and date. Search only Chinese and English literature. The database search was carried out in the form of subject headings combined with free words. The search terms included "hypoxic ischemic encephalopathy," "neonates," and "hypothermia." In addition, references to the included literature were traced back to supplement the acquisition of relevant literature.

#### 2.4. Selection of studies

Two reviewers will independently review the titles, abstracts, and full text of the studies for eligibility for inclusion in this systematic review. All studies searched by electronic databases and identified by hand will be organized in Endnote X7 (Thomson Reuters, New York, NY). Any disagreement between the 2 reviewers will be

resolved by discussion and consensus. If necessary, a third reviewer will intervene and resolve any disagreement.

#### 2.5. Data extraction

Two review authors will independently extract the data and fill out the standard data extraction form, which includes study information such as the first author, publication year, title, journal name, research design, number of patients, inclusion criteria, interventions, control, treatment period, outcome measures, and adverse events. Data extraction will be performed by 2 independent investigators according to a predesigned review form. Disagreements are resolved through discussion among all authors.

#### 2.6. Risk of bias assessment

Two reviewers will assess the risk of bias of the included studies by the "Risk of Bias Assessment Tool" of the Cochrane Handbook for RCTs.<sup>[12]</sup> The evaluation contents include random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other biases. Each item is divided into "high risk," "unclear risk," and "low risk." Any inconsistencies will be determined in consultation with the third reviewer.

#### 2.7. Data synthesis and analysis

Statistical analysis will be performed with Review Manager software 5.3 (Cochrane Collaboration, Nordic Cochrane Center, Copenhagen, Denmark). Relative risk is used to evaluate the effect size for binary variables, and the mean difference is used as the efficacy analysis statistic for continuous variables. Heterogeneity between results will be assessed by the value of Pand  $I^2$ . When P > .1,  $I^2 < 50\%$ , it will be considered as no significant heterogeneity between the trials, and the fixed-effect model will be applied for statistics, otherwise, the random-effect model will be chosen.

#### 2.8. Sensitivity analysis

If the risk of bias of the studies is high, sensitivity analysis will be performed to investigate the asymmetry of funnel plots to exclude low-quality studies.

#### 2.9. Assessment of quality of evidence

We will use the Grading of Recommendations Assessment, Development, and Evaluation to assess the results.<sup>[13]</sup> In the Grading of Recommendations Assessment, Development, and Evaluation system, the quality of evidence will be categorized into 4 levels: high, moderate, low, and very low quality.

# 3. Discussion

Evidence from RCTs has confirmed that therapeutic hypothermia to neonates with moderate to severe NE resulted into reduction in mortality and major neurodevelopmental disability at 18 months of age.<sup>[14]</sup> As a result, therapeutic hypothermia is currently the mainstay of treatment in neonates with moderate or severe NE.<sup>[15]</sup> Neonates with mild NE were not part of the eligibility criteria in the trials of therapeutic hypothermia as they were previously considered to have good long-term outcomes.

Recently, evidence is emerging that even mild NE can adversely affect long-term neurodevelopmental outcomes. Studies have suggested that without the application of therapeutic hypothermia, neonates with mild NE have equal risk of having brain magnetic resonance imaging abnormality (54% in mild vs 54% in moderate encephalopathy) and disability as compared with the infants with moderate encephalopathy at 5 years of age.<sup>[16]</sup> However, the beneficial effects of therapeutic hypothermia in mild NE must be proven in high quality studies before it could be used as a standard of care. To the best of our knowledge, this is the first meta-analysis of RCTs to evaluate the effectiveness of therapeutic hypothermia for mild NE. These clues and conclusion are hoped to encourage researchers to conduct further research on the subject.

# **Author contributions**

Conceptualization: Xini Liu. Data curation: Tingting Zheng, Xini Liu. Funding acquisition: Xini Liu, Xuechun Chen. Investigation: Tingting Zheng. Methodology: Xini Liu. Writing – original draft: Tingting Zheng. Writing – review & editing: Xuechun Chen.

#### References

- Lawn JE, Blencowe H, Oza S, et al. Every newborn: progress, priorities, and potential beyond survival. Lancet 2014;384:189–205.
- [2] Gunn AJ, Thoresen M. Neonatal encephalopathy and hypoxic-ischemic encephalopathy. Handb Clin Neurol 2019;162:217–37.
- [3] Schump EA. Neonatal encephalopathy: current management and future trends. Crit Care Nurs Clin North Am 2018;30:509–21.

- [4] McIntyre S, Nelson KB, Mulkey SB, Lechpammer M, Molloy E, Badawi N. Neonatal encephalopathy: focus on epidemiology and underexplored aspects of etiology. Semin Fetal Neonatal Med 2021;26:101265.
- [5] Wiswell TE. Evaluation for the etiology of neonatal encephalopathy and the diagnosis of FIRS. Semin Fetal Neonatal Med 2020;25:101140.
- [6] Mrelashvili A, Russ JB, Ferriero DM, Wusthoff CJ. The Sarnat score for neonatal encephalopathy: looking back and moving forward. Pediatr Res 2020;88:824–5.
- [7] McDouall A, Wassink G, Bennet L, Gunn AJ, Davidson JO. Challenges in developing therapeutic strategies for mild neonatal encephalopathy. Neural Regen Res 2022;17:277–82.
- [8] Walsh BH, Neil J, Morey J, et al. The frequency and severity of magnetic resonance imaging abnormalities in infants with mild neonatal encephalopathy. J Pediatr 2017;187:26–33.
- [9] Chalak LF, Nguyen KA, Prempunpong C, et al. Prospective research in infants with mild encephalopathy identified in the first six hours of life: neurodevelopmental outcomes at 18-22 months. Pediatr Res 2018;84:861–8.
- [10] Lally PJ, Montaldo P, Oliveira V, et al. Residual brain injury after early discontinuation of cooling therapy in mild neonatal encephalopathy. Arch Dis Child Fetal Neonatal Ed 2018;103:F383–7.
- [11] Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1.
- [12] Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
- [13] Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ 2004;328:1490.
- [14] Laptook AR, Shankaran S, Tyson JE, et al. Effect of therapeutic hypothermia initiated after 6 hours of age on death or disability among newborns with hypoxic-ischemic encephalopathy: a randomized clinical trial. JAMA 2017;318:1550–60.
- [15] Prashantha YN, Suman RP, Nesargi S, Chandrakala BS, Balla KC, Shashidhar A. Therapeutic hypothermia for moderate and severe hypoxic ischaemic encephalopathy in newborns using low-cost devicesice packs and phase changing material. Paediatr Int Child Health 2019;39:234–9.
- [16] Brocard C, Belaroussi Y, Labat J, Delmas J, Brissaud O, Chateil JF. Brain MRI after therapeutic hypothermia in asphyxiated newborns: predictive value at one year of imaging features. Eur J Radiol 2021;139:109724.